Promising Treatments in Juvenile Dermatomyositis.

Juvenile dermatomyositis (JDM) is an autoimmune systemic connective tissue disorder treated by various anti-inflammatory and immunomodulating agents. JDM typically requires immunomodulatory therapies including corticosteroids, disease-modifying antirheumatic drugs, intravenous immunoglobulins, and other steroid-sparing therapies. It is important to also employ nonpharmacologic interventions, which are integral in the treatment of JDM to optimize outcomes. These include photoprotection, physical therapy, occupational therapy, and mental health support. There are increasing number of exciting, emerging therapies including as Janus kinase-inhibitors, CAR-T cells, and interferon blockers. This review will provide summary of current JDM treatments and some promising newly emerging therapies.